Literature DB >> 22997049

The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy.

Ákos Fábián1, György Vereb, János Szöllősi.   

Abstract

Cancer stem cell (CSC) biology is a rapidly developing field within cancer research. CSCs are postulated to be a unique cell population exclusively capable of infinite self renewal, multilineage differentiation and with ability to evade conventional cytotoxic cancer therapy. These traits distinguish CSCs from their more differentiated counterparts, which possess only limited or no potential for self renewal and tumor initiation. Therefore, CSCs would be the driving motor of malignant growth and therapy resistance. Accordingly, successful cancer treatment would need to eliminate this highly potent group of cells, since even small residual numbers would suffice to recapitulate the disease after therapy. Putative CSCs has been identified in a broad range of human malignancies and several cell surface markers have been associated with their stem cell phenotype. Despite all efforts, a pure CSC population has not been isolated and often in vitro clonogenic and in vivo tumorigenic potential is found in several cell populations with occasionally contradictory surface marker signatures. Here, we give a brief overview of recent advances in CSC theory, including the signaling pathways in CSCs that also appear crucial for stem cells homeostasis in normal tissues. We discuss evidence for the interaction of CSCs with the stromal tumor environment. Finally, we review the emerging potentially effective CSC-targeted treatment strategies and their future role in therapy.
Copyright © 2012 International Society for Advancement of Cytometry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22997049     DOI: 10.1002/cyto.a.22206

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  17 in total

Review 1.  Cell cycle regulation during neurogenesis in the embryonic and adult brain.

Authors:  Arquimedes Cheffer; Attila Tárnok; Henning Ulrich
Journal:  Stem Cell Rev Rep       Date:  2013-12       Impact factor: 5.739

Review 2.  Of Cytometry, Stem Cells and Fountain of Youth.

Authors:  Dariusz Galkowski; Mariusz Z Ratajczak; Janusz Kocki; Zbigniew Darzynkiewicz
Journal:  Stem Cell Rev Rep       Date:  2017-08       Impact factor: 5.739

3.  Melanoma initiating cells: where do we stand?

Authors:  Vincenzo Villani; Francesco Sabbatino; Cristina R Ferrone; Soldano Ferrone
Journal:  Melanoma Manag       Date:  2015-05-18

Review 4.  Cancer stem cells: a systems biology view of their role in prognosis and therapy.

Authors:  Susan D Mertins
Journal:  Anticancer Drugs       Date:  2014-04       Impact factor: 2.248

Review 5.  Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis.

Authors:  Deepika Neelakantan; David J Drasin; Heide L Ford
Journal:  Cell Adh Migr       Date:  2014-10-16       Impact factor: 3.405

Review 6.  Advantages and clinical applications of natural killer cells in cancer immunotherapy.

Authors:  Erik Ames; William J Murphy
Journal:  Cancer Immunol Immunother       Date:  2013-08-30       Impact factor: 6.968

7.  Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.

Authors:  Xiao Ding; He Cao; Xiao Chen; Haofan Jin; Ziling Liu; Guanjun Wang; Lu Cai; Dan Li; Chao Niu; Huimin Tian; Lei Yang; Yuguang Zhao; Wei Li; Jiuwei Cui
Journal:  J Transl Med       Date:  2015-05-13       Impact factor: 5.531

Review 8.  Regulation of miRNAs affects radiobiological response of lung cancer stem cells.

Authors:  Yan-mei Xu; Xing-yun Liao; Xie-wan Chen; De-zhi Li; Jian-guo Sun; Rong-xia Liao
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

Review 9.  Hitting the Bull's-Eye in Metastatic Cancers-NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death.

Authors:  Stephen John Ralph; Rhys Pritchard; Sara Rodríguez-Enríquez; Rafael Moreno-Sánchez; Raymond Keith Ralph
Journal:  Pharmaceuticals (Basel)       Date:  2015-02-13

10.  A novel pathogenic classification of cancers.

Authors:  Carlos Sonnenschein; Barbara Davis; Ana M Soto
Journal:  Cancer Cell Int       Date:  2014-11-30       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.